Phase III Cat-PAD Study
A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Sponsor: Circassia Limited
This PHASE3 trial investigates Rhinoconjunctivitis and is currently completed. Circassia Limited leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Circassia Limited
- Pharm-Olam International
- inVentiv Health Clinical
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States , Bangor, United States , Bardejov, Slovakia , Barnaul, Russia , Bellevue, United States , Berlin, Germany , Blue Bell, United States , Bonn, Germany , Bozeman, United States , Bramsche, Germany and 108 more locations